Bind, Pfizer in Accurins deal
Bind Therapeutics Inc. (Cambridge, Mass.) and Pfizer Inc. (NYSE:PFE) partnered to develop and commercialize Accurins using undisclosed small molecules provided by the pharma for undisclosed diseases. Accurins are selective and programmable nanoparticle-encapsulated therapeutics that are designed to accumulate at the site of disease. Bind -- formerly Bind Biosciences Inc. -- will use its Medicinal Nanoengineering technology to develop the Accurins.
Bind and Pfizer will jointly conduct preclinical development. Pfizer will have an exclusive option to license the Accurins and will be responsible for all clinical development and commercialization. Bind is eligible for up to $50 million in an up front payment and development milestones. The biotech also is eligible for about $160 million in regulatory and sales milestones for each Accurin, plus tiered royalties. ...